Document is current

Article History

Received: 28 March 2025

Accepted: 1 August 2025

First Online: 4 September 2025

Declarations

:

: Anna Balato has served as consultant and/or has received fees from: AbbVie, Almirall, Amgen, BMS, Boehringer Ingelheim, Eli Lilly, LEO Pharma, Janssen, Sanofi, and UCB. Anna Campanati has served as a speaker or board member for AbbVie, Almirall, Galderma, Celgene, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, and UCB; and is a current Editorial Board member for Dermatology and Therapy. Antonio Costanzo has served as a speaker or board member for AbbVie, Amgen, Galderma, Celgene, LEO Pharma, Eli Lilly, Boehringer Ingelheim, Novartis, Pfizer, and UCB. Paolo Gisondi is a current Editorial Board member for Dermatology and Therapy. Martina Burlando, Andrea Chiricozzi, Piergiorgio Malagoli, and Giuseppe Micali declare that they have no competing interests.

: This article is based on previously conducted studies and does not contain any new studies (with human participants or animals) performed by any of the authors. Ethical approval was not required. All dermatologists signed a contract when they agreed to participate in the Psoriasis Working Group; the contract outlined the objectives of the advisory boards and stated that the voting results would be published. Dermatologists’ data were protected by electronic storage with advanced security technologies and periodic backups to protect data integrity and confidentiality.The study sponsor (Novartis) selected the advisory board participants based on their clinical experience in managing patients with psoriasis but had no subsequent input into the project.